– USA, MA – Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, announced the appointment of Dr. Mikael Dolsten (M.D., Ph.D.) to its Board of Directors.
About Dr. Mikael Dolsten
Dr. Mikael Dolsten most recently served as CSO and President of Worldwide Research, Development, and Medical at Pfizer Inc., where he led R&D strategy and portfolio advancement for more than 16 years.
A physician-scientist and biopharma leader, Dr. Mikael Dolsten played a central role in developing and advancing breakthrough innovations across small molecules, biologics, gene therapies, and vaccines, including leading the company’s scientific response to the COVID-19 pandemic. His leadership has shaped portfolios at several global pharmaceutical companies, including Boehringer Ingelheim, AstraZeneca, and Wyeth, and he has contributed to corporate transactions valued at over $100 billion.
Dr. Dolsten currently serves on the public boards of Agilent Technologies and Rocket Pharmaceuticals and holds advisory roles with several notable business groups, including Blackstone Life Sciences, GV, Bain & Company, and Formation Bio. He also holds board or advisory positions with several private biotechnology companies, including Orbis Medicine, ImmuneAI, Fair Journey Biologics, Orogen Therapeutics, Quarry Thera, and ChAI Discovery. Dr. Dolsten is a Visiting Professor at Lund University and a member of the Royal Swedish Academy of Engineering Sciences, and has advised U.S. and U.K. leadership on public health and pandemic preparedness.
About Arbor Biotechnologies, Inc
Arbor Biotechnologies, a clinical-stage, next-generation gene editing company based in Cambridge, MA, is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to the most common genetic diseases. The company’s unique suite of optimized gene editors, capable of gene knockout, excisions, reverse transcriptase editing, and large gene insertions, goes beyond the limitations of early editing technologies to unlock new targets and fuel a robust pipeline of first-in-class assets focused on diseases of high unmet need. With its lead program, ABO-101 for primary hyperoxaluria type 1, progressing into clinical trials, Arbor continues to focus on genomic diseases of the liver and CNS for which there are no existing functional cures.
For more: https://www.arbor.bio
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.